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ABSTRACT  17 
Perfluorinated alkyl substances have been in use for over sixty years, and these highly stable 18 
substances were at first thought to be virtually inert and of low toxicity. Toxicity information 19 
slowly emerged on perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS). More 20 
than 30 years ago, early studies reported immunotoxicity and carcinogenicity effects. The 21 
substances were discovered in blood samples from exposed workers, then also in the general 22 
population and in community water supplies near U.S. manufacturing plants.  Only recently has 23 
research publication on PFOA and PFOS intensified. While the toxicology data base is still far 24 
from complete, carcinogenicity and immunotoxicity now appear to be relevant risks at prevalent 25 
exposure levels. Existing drinking water limits are based on less complete evidence that was 26 
available before 2008 and may be more than 100-fold too high. As risk evaluations assume that 27 
untested effects do not require regulatory attention, the greatly underestimated health risks from 28 
PFOA and PFOS illustrate the public health implications of assuming safety of incompletely 29 
tested industrial chemicals.   30 
 31 
Keywords: Carcinogen, Exposure limit, Immunotoxicant, Perfluorinated octanoic acid, 32 
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Introduction 35 
Poly- and perfluorinated alkyl substances (PFASs) have been in use for over 60 years [1].  First 36 
manufactured by the 3M Company in Cottage Grove, Minnesota, perfluorooctanoic acid (PFOA) 37 
was a primary PFAS product, but perfluorooctane sulfonate (PFOS) and other PFASs were also 38 
produced. By about 2000, their global environmental dispersion became publicly known. A 39 
phase-out of commercial PFOS production by the end of 2002 was announced by 3M in 2000, 40 
and eight major US producers have agreed to phase out PFOA no later than 2015. Recent reports 41 
on adverse effects [2, 3] suggest that the toxicity of these substances has long been 42 
underestimated. 43 
The PFAS show high thermal, chemical and biological inertness – properties that make 44 
them useful for certain industrial purposes, but persistence may also create an environmental 45 
hazard [4]. The strong carbon-fluorine bond renders the PFASs highly persistent in the 46 
environment and in the human body. However, the functional group at the end of the 47 
perfluorinated carbon chain made the PFASs far from inert. By the 1970s, the physical and 48 
chemical properties were well known [5, 6]. Thus, many PFASs can leach through soil to reach 49 
the groundwater, while some PFASs may evaporate and disseminate via the atmosphere [7]. 50 
Although most of them are oleophobic and do not accumulate in fatty tissues (unlike dioxins and 51 
other persistent halogenated compounds), they were later found to bioaccumulate in aquatic and 52 
marine food chains, especially PFOS [8]. Thus, as criteria for persistent, bioaccumulative and 53 
toxic chemicals were developed and refined in the 1990s [9], the PFAS physical and chemical 54 
properties should have raised warning signs. 55 
Little was published in scientific journals on PFAS toxicology until the 1980s, perhaps 56 
because compounds resistant to breakdown were erroneously considered inert [10]. The present 57 
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overview relies on recent reviews, such as the ATSDR draft Toxicological Profile [7], a draft 58 
risk assessment developed by the US Environmental Protection Agency, and recent overviews 59 
[2, 11-13]. Our objective is to illustrate the problems that can result from the regulatory 60 
assumption that untested chemicals are safe. We focus on PFOS and PFOA as the substances 61 
with the best available information to review the emergence of new insight into carcinogenicity 62 
and immunotoxicity as potential critical effects [2, 14]. We focus our comments on these two 63 
effects because of their long history of scientific study, while recognizing that other adverse 64 
health effects have recently been documented (C8SciencePanel, 2013). Although mainly relying 65 
on published information, we are aware that a major chemical company was fined by the 66 
U.S.EPA for failing to comply with the legal requirement of reporting information to the EPA 67 
about substantial risk of injury to human health or the environment due to PFAS [15]. A 68 
chronology of important events in understanding PFAS health risks is provided in Table 1 [16]. 69 
 70 
Human exposure to perfluorinated compounds 71 
The existence of PFASs in the human body was first suspected in the late 1960s when fluoride in 72 
blood samples was found to be partially bound to organic compounds of unknown structure [17]. 73 
High concentrations in exposed workers were documented in the 1970s [18], and specific PFASs 74 
were later identified in serum samples from workers at production facilities [19] in accordance 75 
with the ready absorption of the compounds in laboratory animals after oral or inhalation 76 
exposure [20].  77 
Multiple sources play a role for exposures of the general population,  and human 78 
exposures include precursor compounds that may be broken down into PFOA and PFOS [1]. In 79 
the Mid-Ohio Valley of the US, drinking water supplies were contaminated with PFOA in the 80 
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1980s from an industrial facility [21], and aquifers in Minnesota were also contaminated from a 81 
production plant [22]. Concentrations of PFOA in many water samples exceeded 1 µg/L (1,000 82 
ng/L), with concentrations of PFOS being almost as high [7]. Other routes of human exposure 83 
are primarily from consumer product use, and degradation or improper disposal of PFAS-84 
containing materials, including food-wrapping [1, 23, 24]. 85 
Analysis of serum samples from the National Health and Nutrition Examination Survey 86 
(NHANES) about year 2000 showed that PFOS and PFOA were detectable in all Americans 87 
[25]. Median concentrations in serum were about 30 ng/mL (PFOS) and 5 ng/mL (PFOA). The 88 
average had decreased 8-10 years later to less than half for PFOS, while PFOA had changed 89 
much less [26, 27]. PFASs are transferred through the human placenta and via human milk [28, 90 
29]. Overall, serum concentrations in children tend to be higher than in adults [30]. 91 
Serial analyses of serum samples from former 3M production workers after retirement 92 
suggested elimination half-lives for long-chain PFASs to be ~3years (PFOA) and ~5years 93 
(PFOS) [31]. Declines in serum-PFOA concentrations after elimination of the water 94 
contamination suggest a median elimination half-life of 2.3 years [32], thus confirming the 95 
persistence of PFAS in the human body.  96 
 97 
Adverse health effects 
The main evidence on adverse effects in humans comes from observational studies of cohorts of 
production workers and community studies of subjects exposed either at background levels or 
through contaminated drinking water. Some studies are hampered by imprecise estimates of 
long-term PFAS exposures and may for this reason have underestimated the effects [33]. Follow-
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up studies of workers have largely shown an overall mortality deficit [34-36], thus most likely 
reflecting the presence of a ‘healthy worker’ effect [37].  
New evidence has emerged, as a settlement agreement in 2005 established the C8 Health 
project, where data on approximately 70,000 exposed Ohio and West Virginia residents provided 
information on drinking water intake, measured and calculated serum-PFOA concentrations, and 
a variety of possible clinical outcomes [38, 39]. Additional evidence on associations between 
PFAS exposure and disease parameters in the general population comes from the NHANES data 
base, which provides national data for exposures to environmental chemicals that can be linked 
to concurrent health information on the study participants [25].  
In regard to experimental toxicity studies, most published reports are based on the rat, 
which eliminates PFAS much more rapidly than humans and therefore is not an ideal species 
[12]. Even today, chronic toxicity studies in other species are lacking, and a formal cancer 
bioassay has not yet been completed. In addition, insufficient attention had been paid to 
exposures during sensitive developmental stages.  
 
Cancer 
The rodent cancer bioassay has long served as a key component of carcinogenicity assessment 
[40]. Evidence on cancer risks in rodents exposed to PFASs and other peroxisome proliferating 
substances, which promote rapid cell division, originates from the late 1970s, specifically in 
regard to pancreatic tumors and hepatocellular carcinomas [41-43]. For Leydig cell tumors, the 
first evidence describing the tumor mechanisms was published in 1992 [44], and further review 
of cancer mechanisms appeared in the late 1990s [45].  
7 
 
The Dupont cancer surveillance system has been monitoring cancer incidence in workers 
as far back as 1956 [46], and an internal report showed increased leukemia incidence in 
employees at a PFOA production plant. As a result of the 3M findings (see below) and animal 
carcinogenicity studies showing increased male reproductive organ cancer, prostate cancer has 
been monitored in DuPont workers from 1998, although the results have apparently not been 
released. An updated cancer surveillance report covered the years 1956-2002 showed excess 
kidney cancer (SIR=2.3, 95% confidence interval [CI] 1.36-3.64), bladder cancer (SIR=1.93, 
95% CI 1.14-3.06), and myeloid leukemia (SIR=2.25, 95% CI 1.03-4.28) in the employees, and 
an elevated, but not statistically significant, risk of testicular cancer (SIR=1.46, 95% CI 0.47-
3.41) [47].  
Initially the most important 3M worker study was Frank Gilliland’s thesis project on 
retrospective mortality of 2788 male and 749 female production workers during 1947-1984. 
Based on four cases, an excess occurrence of prostate cancer was found (SMR=3.3, 95% CI 
1.02-10.6) in PFOA-exposed workers with greater than ten years of employment [34]. There 
were subsequent analyses of cancer in 3M workers after reported further evidence of increased 
prostate cancer risk, but not for other cancers [48, 49].  The key epidemiologic studies are 
summarized in Table 2. Incomplete follow-up, uncertainties in exposure assessment, and 
incomplete ascertainment of cancer mortality limit the conclusions that can be drawn from this 
evidence.  
The EPA draft risk assessment of PFOA reviewed the published animal and human 
epidemiologic studies up to 2005 and concluded that the evidence was “suggestive” of a cancer 
risk in humans. When reviewing the same evidence a year later, the majority of an expert 
committee recommended that PFOA be considered “likely to be carcinogenic to humans” [50].  
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This conclusion is supported by the recent C8 Health Project results [51]. Thus, two 
different epidemiological approaches [52, 53] support the association between PFOA exposure 
and both kidney and testicular cancer and suggest associations with prostate and ovarian cancer 
and non-Hodgkin lymphoma. The C8 Science Panel specifically listed kidney cancer and 
testicular cancer as having a "probable link" to C8. Although PFOA should therefore be 
considered a "likely" human carcinogen based on sufficient evidence in experimental animals 
and limited evidence in human epidemiology studies, current regulations of PFASs are based not 
on carcinogenicity but on developmental toxicity and changes in liver weight.  
Mechanisms of cancer development are now being explored [2, 54]. Among possible 
mechanisms, induction of hormone-dependent cancer has been suggested in rodent studies [55]. 
Developmental exposure to PFOA induces effects that are not necessarily seen in response to 
exposures during adulthood [55], as reflected by endocrine disruption effects in humans exposed 
to PFASs during early development [56, 57]. 
 
Immunotoxicity 
Among early toxicology studies [20], immunotoxicity was considered a main effect in a rhesus 
monkey study sponsored by 3M [58], although the report was not published in the open 
literature. Four monkeys exposed to subacute toxicity from the ammonium PFOA salt showed 
atrophied thymus, diffuse atrophy of lymphoid follicles of the spleen, and other signs of 
immunotoxicity. Researchers at the time were well aware of the adverse effects to the 
“reticuloendothelial system”, and increasing attention was being paid to adverse effects on 
immune functions [59]. However, these findings did not lead to further exploration of 
immunotoxic risks associated with PFAS exposure until decades later. Routine parameters, such 
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as spleen microscopy and general clinical chemistry, failed to show any significant effects in 
non-human primates [60].  
In recent years, immunotoxicity of PFCs has been demonstrated in a wide variety of 
species and models [14]. In the mouse, PFOA exposure caused decreased spleen and thymus 
weights, decreased thymocyte and splenocyte counts, decreased immunoglobulin response, and 
changes in specific populations of lymphocytes in the spleen and thymus [7, 14]. Reduced 
survival after influenza infection was reported in mice as an apparent effect of PFOS exposure 
[61]. When injection of sheep erythrocytes was used as antigen exposure in the mouse model, the 
lowest observed effect level (LOEL) for a deficient antibody response corresponded to average 
serum concentrations of 92 ng/g and 666 ng/g for male and female mice, respectively [62]. These 
serum concentrations are similar to or slightly exceed those prevalent in residents exposed to 
contaminated drinking water [21, 63, 64]. Although a 3M-supported study reported no 
immunological effects at a high dietary PFOS exposure in the same strain of mice [65], another 
study of gestational exposure confirmed that male pups were more sensitive than females and 
that developmental exposure can result in functional deficits in innate and humoral immunity 
detectable at adulthood [66].  
In human studies, childhood vaccination responses can be applied as feasible and 
clinically relevant outcomes, because children have received the same antigen doses at the same 
ages [67]. In the fishing community of the Faroe Islands, PFOS in maternal pregnancy serum 
showed a strong negative correlations with antibody concentrations in 587 children at age 5 
years, where a doubling in exposure was associated with a difference of -41% (p = 0.0003) in the 
diphtheria antibody concentration [3]. PFCs in the child’s serum at age 5 showed negative 
associations with antibody levels at age 7, and a doubling in PFOS and PFOA concentrations 
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was associated with differences in antibody levels between -24 and -36% (joint effect of -49%, p 
= 0.001). For doubled concentrations at age 5, PFOS and PFOA showed odds ratios between 2.4 
and 4.2 for falling below a clinically protective antibody level of 0.1 IU/mL for tetanus and 
diphtheria at age 7 [3]. Serum concentrations of both PFASs are similar to, or lower than, those 
reported from the US population. 
A study of 99 Norwegian children at age 3 years found that maternal serum PFOA 
concentrations were associated with a decreased vaccine responses, especially toward rubella 
vaccine, and increased frequencies of common cold and gastroenteritis [68]. In a larger study, 
PFOS and PFOA concentrations in serum from 1400 pregnant women from the Danish National 
Birth Cohort were not associated with the hospitalization rate for infectious disease (including 
such diagnoses as pneumonia or appendicitis) in 363 of the children up to an average age of 8 
years [69].  In adults, PFOA exposure was associated with lower serum concentrations of total 
IgA, IgE (females only), though not total IgG [70]. In the exposed Ohio Valley population, 
elevated serum-PFOA concentrations were associated with reduced antibody titer rise after 
influenza vaccination [71]. Taking into account the likely sensitivity of the various outcome 
measures as indication of PFAS immunotoxicity, the combined human and experimental 
evidence is in strong support of adverse effects on immune functions at current exposure levels.  
In regard to mechanisms of immunotoxicity, PPAR receptor activation may play a role 
[7, 14]. However, experimental evidence suggests independence of PPARα for at least some of 
PFOA’s immunotoxic effects, as shown in PPARα knockout models [72]. White blood cells 
from human volunteers showed effects even at the lowest in vitro PFOS concentration applied, 
i.e., 0.1 µg/mL (or 100 ng/mL) [73]. This level is similar to concentrations seen both in affected 
male mice [62] and in US residents exposed to contaminated drinking water [21, 63, 64].  
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Implications for prevention 1 
The U.S.EPA first issued a draft risk assessment of PFOA in 2005, but a final, quotableversion 2 
has yet to appear. While a Reference Dose (RfD) is not available, the EPA in 2009 published 3 
provisional drinking water health advisories of 0.4 µg/L (400 ng/L) for PFOA and 0.2 µg/L (200 4 
ng/L) for PFOS [4]. EPA used calculations of benchmark dose level (BMDL) from experimental 5 
toxicology studies and concluded at the time that ‘[e]pidemiological studies of exposure to 6 
PFOA and adverse health outcomes in humans are inconclusive at present’. The same toxicology 7 
data published by the end of the last decade were used for derivation of drinking water limits 8 
authorized by US states and EU countries as well as the EU Tolerable Daily Intakes for PFOA 9 
and PFOS [74], although different default assumptions and uncertainty factors were applied.  10 
BMDL is recommended by the EPA and other regulatory agencies as a basis for 11 
calculations of safe levels of exposures [75, 76]. As the BMDL is not a threshold, this lower 95% 12 
confidence limit is applied as a point of departure, and the guidelines proscribe a default 10-fold 13 
uncertainty factor to be used for calculation of an exposure limit.  14 
Table 3 lists relevant BMDL results in terms of serum concentrations. A sensitive 15 
outcome at first appeared to be the increase in liver weight; Leydig cell tumor formation was 16 
considered as a dose-dependent outcome and appeared to be less sensitive [77]. The same was 17 
truef or immune system toxicity that was generally evaluated by differential leukocyte counts 18 
and microscopic examination of lymphoid tissues, sometimes complemented with a cell 19 
proliferation test [78]; functional tests were not conducted. In terms of serum concentrations, the 20 
BMDLs were 23 µg/mL serum for PFOA and 35µg/mL for PFOS [22]. Expression of the BMDL 21 
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in terms of the serum concentration is particularly useful, as it facilitates interspecies 22 
comparisons by taking into account toxicokinetic differences. 23 
Recent data on mammary gland development in mice suggest that clear effects may result 24 
from much lower developmental exposures [2]. Benchmark dose calculations using a variety of 25 
models correspond to a serum concentration of 23-25 ng/mL [12], i.e., one-thousandth of the 26 
BMDL based on liver toxicity. Benchmark calculations are not available in regard to 27 
immunotoxic effects in mice and cannot easily be estimated from published data [14], but would 28 
likely be orders of magnitude below previously calculated BMDLs. 29 
Using the data from the recent study of immunotoxicity in children [3] and assuming a 30 
linear dose-dependence of the effects, BMDLs were calculated to be approximately 1.3 ng/mL 31 
for PFOS and 0.3 ng/mL for PFOA, both in terms of the serum concentration  [79]. Using an 32 
uncertainty factor of 10 to take into account individual susceptibility, the BMDLs would  33 
therefore result in a Reference Dose (RfD) serum concentration of about or below 0.1 ng/mL. 34 
The experimental data require at least an additional interspecies 3-fold uncertainty factor for 35 
interspecies differences in toxicodynamics [76]. Thus, using a total uncertainty factor of 30, the 36 
RfD based on mammary gland development in mice would correspond to a serum-PFOA 37 
concentration of 0.8 ng/mL. As the experimental studies that the regulatory agencies have relied 38 
upon so far correspond to serum concentrations 1000-fold higher, current limits for water 39 
concentrations of PFOS and PFOA appear to be too high by at least two orders of magnitude.   40 
For comparison, an approximate limit for drinking water can be estimated by an 41 
independent calculation. PFOA concentrations in drinking water and in the serum of residents 42 
are highly correlated [21, 80], and the calculated ratio of one-hundred-fold between the 43 
concentrations in the two media could therefore be used to calculate a concentration in drinking 44 
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water that would correspond to the RfD expressed in terms of the serum concentration. 45 
Assuming no other sources of exposure, a serum concentration of 0.1 ng/mL would correspond 46 
to a water concentration of approximately 1 ng/L, or 0.001 µg/L. Although neither of the two 47 
sets of calculations in any way represents a formal risk evaluation, it is noteworthy that current 48 
limits are generally several hundred-fold higher than recent BMDL results would seem to justify.  49 
 50 
Discussion 51 
The PFASs have been in use for many decades, but their otherwise useful properties 52 
unfortunately result in persistence and dissemination in the environment. The toxic properties 53 
were initially explored in the 1970s, but the toxicological data base has expanded only after 54 
environmental dissemination recently became known.  55 
In the United States, the Toxic Substances Control Act (TSCA) has been in force since 56 
the late 1970s, but did not require testing of substances, such as PFASs, already in commerce at 57 
the time. Perhaps the TSCA even discouraged chemicals producers from testing substances that 58 
had already received blanket approval [81]. The voluntary decision in 2000 to phase-out PFOS 59 
production in the US coincided with the first demonstration of environmental persistence and 60 
dissemination of PFASs.  61 
Although comparatively few articles on PFASs were published in scientific journals prior 62 
to 2008 [82], our understanding of the toxicity of these compounds has its roots in studies 63 
already carried out in the late 1970s. Thus, more than 30 years ago, possible carcinogenicity and 64 
immunotoxicity had already been demonstrated in experimental studies, and they were 65 
complemented by internal company surveillance of birth defects, mortality and clinical findings 66 
in workers. These reports could have inspired in-depth studies, but apparently did not.   67 
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Thus, as judged from available publications, the early leads were not followed up with 68 
the focused research that in today’s perspective would have seemed appropriate. Of note is also 69 
the EPA decision to fine a company for violation of the duty to report adverse effects of PFAS 70 
and the subsequent court-mandated health studies [15, 39]. Had the first suspicions of health 71 
risks from PFAS exposures been explored in systematic research and testing, they could perhaps 72 
have triggered earlier and more vigorous efforts to control exposures to workers and to prevent 73 
community contamination and global dissemination.  74 
The PFASs therefore provide an example of the “untested-chemical assumption” that  the 75 
lack of documentation means that no regulatory action is required [83]. In this case, the 76 
assumption ignored preliminary evidence on plausible effects and did not inspire further 77 
exploration. The present overview suggests that these assumptions resulted in continued PFAS 78 
dissemination and exposure limits that may be more than 1,00-fold too high to adequately protect 79 
the general population against adverse health effects. Clearly, the absence of documentation from 80 
epidemiological studies should not be considered as a reason to conclude that adverse effects 81 
have not and will not occur [84]. Thus, the PFASs represent an example of a failed scientific and 82 
regulatory approach [83], and thereby also document the need for better linkage between 83 
research and risk assessment to inspire prudent chemicals control policies.  84 
85 
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Table 1. Time course of important developments regarding PFAS exposure and health risks.* 306 
307 Year Event 
1947 PFAS production starts at 3M plant in Cottage Grove, MN 
1962 Internal Dupont document raises concern about health risks 
1970s PFAS vapor pressures and water solubilities in chemical handbooks 
1978 Unpublished monkey study reveals immunotoxicity and other adverse effects due to 
PFOA 
1980 Organic fluoride determined in serum from production workers 
1981 Concern about birth defects in children of female production workers 
1987 PFOA carcinogenicity reported in rat study  
1993 3M begins to monitor PFOA in serum from production workers 
Mortality study shows excess occurrence of prostate cancer 
1998 Serum from US blood donors shown to contain PFAS 
2000 Global dissemination of environmental PFAS contamination documented 
3M announces plan to phase out commercial production of PFOS  
2005 Extensive drinking water contamination discovered in Minnesota  
2008 Health Risk Limits for PFAS in drinking water are issued 
Mouse study shows immunotoxicity at serum PFAS concentrations similar to 
human exposures 
2010 Decrease of PFOA emissions by 95% said to be completed  
2011 PFOA induces delayed mammary gland development in mice at low exposures 
2012 PFAS immunotoxicity reported in children 
Adapted from Grandjean and Clapp[16] 308 
309 
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Table 2. Summary of main cancer epidemiology studies.  310 
 311 
Reference Study population Main results Comments 
 312 
[34] 2788 male and 749 
female workers in 
PFOA production 
plant 
Male all cause 
SMR=0.77 (95% CI 
0.69-0.86); Prostate 
cancer SMR=3.3 (CI 
1.02-10.6) with 10+ 
years employment 
Likely healthy worker 
effect; six prostate 
cancer deaths overall 
[48] 2083 production 
workers employed at 
least one year in 
Alabama  
PFOS fluoride 
production plant 
All cause SMR=0.63 
(95% CI 0.53-0.74); 
Bladder cancer 
SMR=16.12 (95% CI 
3.32-47.14) in those 
with high exposure 
jobs  
Likely healthy worker 
effect; small number 
of cancer deaths, only 
three bladder cancer 
deaths 
[35] 6027 workers who 
worked in DuPont 
West Virginia plant 
between 1948 and 
2002 
All cause SMR=67 
(95% CI 62-72); All 
cancer SMR=74 (95% 
CI 65-84); Kidney 
SMR=152 (95% CI 
78-265) 
Likely healthy worker 
effect; comparison to 
other DuPont Region 
I workers 
unremarkable 
[49] 3993 workers 
employed at least a 
year in Minnesota 
PFOA plant between 
1947 and 1997 
All cause SMR=0.9 
(95% CI 0.7-1.1); 
Prostate cancer 
SMR=2.1 (95% CI 
0.4-6.1); 
Moderate/high 
exposed SMR=3.2 
(95% CI 1.0-10.3) 
Suggestive increased 
mortality from 
bladder cancer and 
cerebrovascular 
disease 
[51] 5791 workers exposed 
to PFOA in DuPont 
West Virginia plant 
All cause SMR=0.98 
(95% CI 0.92-1.04); 
Kidney cancer 
SMR=2.66 (95% CI 
1.15-5.24) in most 
highly exposed 
quartile 
Detailed exposure 
estimates, additional 
results with lagged 
analyses for 
mesothelioma and 
chronic renal disease 
deaths 
[52] Cancer cases and 
controls from five 
West Virginia and 
Ohio counties 
diagnosed 1996-2005 
Kidney cancer 
OR=2.0 (95% CI 1.0-
3.9) for very high 
exposure category; 
Testis cancer OR=2.8 
(95% CI 0.8-9.2) for 
very high exposure 
category 
Community water 
contamination 
estimates showed 
suggestive 
associations with 
several types of 
cancer 
313 
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Table 3. Benchmark dose level (BMDL) results in terms of serum concentrations of PFOA and 314 
PFOS. 315 
Reference Study type BMDL Outcome parameter 
PFOA 
[77] Adult rats with 
subchronic exposure 
23,000 ng/mL 10% increase in liver 
weight 
[2, 12] Developmental 
exposure in mice 
23-25 ng/mL 10% delay in 
mammary gland 
development  
[3] Prospective human 
birth cohort study 
0.3 ng/mL 5% decrease in serum 
concentration of 
specific antibodies 
PFOS 
[78, 85] Adult cynomolgus 
monkeys with 
subchronic exposure 
35,000 ng/mL 10% change in liver 
function and thyroid 
function 
[3] Prospective human 
birth cohort study 
1.3 ng/mL 5% decrease in serum 
concentration of 
specific antibodies 
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